Nanommune, Velox to offer microarray testing, consulting for COVID-19

LabPulse.com staff writers
Jul 2, 2020
2020 07 02 23 31 0378 Handshake Meeting 400

Medical biotechnology company Nanommune and clinical diagnostics company Velox Biosystems have partnered to offer rapid laboratory testing and consulting services.

The partnership aims to increase the adoption of high-plex microarray platforms among clinicians, laboratories, and researchers who want to use microarray technology for COVID-19 diagnostics but lack the experience and capabilities to perform high-throughput testing.

Nanommune and Velox will leverage their diagnostic testing experience to provide end-to-end testing and consulting services for microarray antibody and antigen assays. The companies are also working closely together to launch a COVID-19 immune profiling service and other products based on the microarray technology, according to Velox Chief Executive Officer Byron Shen.

Latest in Gene silencing and gene editing
Crispr Cas9 Gene Editing Social
KSQ Therapeutics receives FDA clearance for trial of CRISPR-Cas9 engineered tumor therapy
November 29, 2023
Sickle Cell Anemia2 Social
U.K. regulators approve "world-first" sickle-cell gene therapy
November 20, 2023
Gene Therapy Dna Scientist Social
U.K. trial approved for Hunter syndrome gene therapy
November 9, 2023
Crispr Cas9 Gene Editing Social
CRISPR Therapeutics to present data from gene therapy programs at AHA Scientific Sessions
November 6, 2023
Related Stories
2020 06 24 16 50 8425 Pathogen Dx 400
Gene silencing and gene editing
PathogenDx partners with Bertin Instruments on airborne COVID-19 test
2019 05 15 19 42 9457 Gavel3 400
Lawsuit
Feds arrest president of blood testing firm on fraud charges
2020 06 04 21 46 9284 2020 06 04 H Vivo 400
Gene silencing and gene editing
Firm offers COVID-19 full sample antibody testing for U.K. employers
2020 05 12 22 10 0813 Child Speech Therapy 400
Research Consortium
Real-world study: Genetic testing appears underused in autism
More in Gene silencing and gene editing
KSQ Therapeutics receives FDA clearance for trial of CRISPR-Cas9 engineered tumor therapy
Biotech firm KSQ Therapeutics has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a phase I and II trial of KSQ-001EX, KSQ’s CRISPR-Cas9 engineered tumor-infiltrating lymphocyte program.
November 29, 2023
Crispr Cas9 Gene Editing Social
U.K. regulators approve "world-first" sickle-cell gene therapy
U.K. medical regulators have approved a “world-first” gene therapy that aims to cure two blood disorders: sickle cell disease and transfusion-dependent β-thalassemia. They are the first regulatory body to approve the treatment.
November 20, 2023
Sickle Cell Anemia2 Social
U.K. trial approved for Hunter syndrome gene therapy
U.K. regulators have approved the “first ever” trial of a revolutionary gene therapy for young children diagnosed with Hunter syndrome, a rare lysosomal storage disorder.
November 9, 2023
Gene Therapy Dna Scientist Social
CRISPR Therapeutics to present data from gene therapy programs at AHA Scientific Sessions
Biopharmaceutical company CRISPR Therapeutics will present preclinical data from its investigational gene therapy treatment programs for cardiovascular disease at the AHA Scientific Sessions 2023 in Philadelphia on November 11.
November 6, 2023
Crispr Cas9 Gene Editing Social
Vertex Pharmaceuticals, CRISPR Therapeutics gene-editing therapy to undergo FDA advisory committee review
An FDA advisory committee is scheduled to meet on October 31 to discuss and make recommendations on Vertex Pharmaceuticals' and CRISPR Therapeutics’ CRISPR-Cas9 gene-editing-based therapy, exagamglogene autotemcel.
October 30, 2023
Fda Sign Dc Social
Software reduces DANGER of CRISPR-Cas9 by shedding light on off-target edits
A new software can improve the safety and utility of CRISPR-Cas9 gene editing by detecting off-target changes and eliminating the need for reference genomes, according to a paper published in Bioinformatics Advances.
October 27, 2023
Crispr Cas9 Gene Editing Social
CRISPR-Cas3 technique restores dystrophin function in iPSCs from DMD patients
Researchers have developed a dual CRISPR-Cas3 gene editing technique to restore dystrophin function in induced pluripotent stem cells (iPSCs) from patients with Duchenne muscular dystrophy (DMD).
August 24, 2023
This photo shows green dystrophin protein restored by dual-Cas3 in skeletal muscle derived from DMD patient iPSCs.
Messenger RNA shows preclinical promise as in vivo gene editing treatment for sickle cell
The delivery of the editing system resulted in the near-complete correction of hematopoietic sickle cells. A preclinical test linked the approach to a 91.7% increase in functional hemoglobin and a significant fall in the number of sickled cells.
August 14, 2023
Sickle Cell Anemia2 Social
Netherlands researchers combine CRISPR, bioluminescence in proof-of-concept infectious disease test
Glow-in-the-dark proteins, developed from the luciferase found in bioluminescent creatures, may make viral disease diagnosis quicker and easier, according to the researchers.
March 15, 2023
Crispr Cas9 Gene Editing Social
Sherlock Biosciences nabs additional patent rights to Cas12 enzyme for CRISPR diagnostics
Sherlock Biosciences has exclusive U.S. rights to the patent from Shanghai-based Tolo Biotech, as well as to additional intellectual property for Cas12 and Cas13 obtained from the Broad Institute.
February 21, 2023
Ms Crisp Rimage Social
Sherlock Biosciences acquires Sense Biodetection to drive CRISPR-based test adoption
The acquisition enables Sherlock to combine its CRISPR, synthetic biology, and artificial intelligence technologies with Sense's instrument-free diagnostic hardware and rapid molecular amplification chemistries.
February 1, 2023
Crispr Cas9 Gene Editing Social
AI tool makes speedy gene-editing possible, offers alternative to CRISPR
An artificial intelligence program may enable the first simple production of customizable proteins called zinc fingers to treat diseases by turning genes on and off.
January 26, 2023
Crispr Cas9 Gene Editing Social
Page 1 of 6
Next Page